Effect of intrathoracic-intraperitoneal perfusion chemotherapy followed by high-frequency hyperthermia therapy in elderly patients with malignant pleural and peritoneal effusions

doi:10.3877/cma.j.issn.2095-8757.2024.02.004

Abstract

Abstract:

Objective

To investigate the effect of intrathoracic-intraperitoneal perfusion chemotherapy followed by high-frequency hyperthermia therapy in elderly patients with malignant pleural and peritoneal effusions.

Methods

A total of 200 elderly patients with malignant pleural and peritoneal effusions who were admitted to Tai'an City Central Hospital from January 2022 to January 2023 were selected. One hundred patients who received intrathoracic-intraperitoneal perfusion chemotherapy alone were assigned to the control group, and the other 100 patients who received intrathoracic-intraperitoneal perfusion chemotherapy followed by high-frequency hyperthermia were assigned to the observation group. After treatment, the amount of pleural and peritoneal effusion was measured under B-mode ultrasound to compare the short-term effects between the two groups. Additionally, the levels of tumor markers, quality of life, and adverse reactions were observed in both groups. T test was used to compare the measurement data, and Chi-square test was used to compare the counting data.

Results

The total effective rate in the observation group was significantly higher than that in the control group (81.00% vs. 68.00%; χ²=4.448, P < 0.05). The levels of tumor markers such as carcinoembryonic antigen, carbohydrate antigen 125, and carbohydrate antigen 199 decreased more significantly in the observation group compared with those in the control group (t=4.574, 7.125, 14.153; P < 0.01). The improvement rate of Karnofsky score was significantly higher in the observation group than that in the control group (82.00% vs. 69.00%; χ²=4.568, P < 0.05). However, there was no statistically significant difference in the incidence of adverse reactions (including gastrointestinal symptoms, neutropenia, thrombocytopenia, liver insufficiency, and renal insufficiency) between the two groups (χ²=0.130, 0.177, 0.411, 0.072, 0.096; P > 0.05).

Conclusion

Intrathoracic-intraperitoneal perfusion chemotherapy followed by high-frequency hyperthermia therapy is safe and reliable in elderly patients with malignant pleural and peritoneal effusions, which can effectively improve short-term efficacy with reducing the levels of tumor markers and improving the quality of life.

Key words: Malignant pleural and peritoneal effusion, Aged, Intrathoracic-intraperitoneal perfusion chemotherapy, High frequency hyperthermia, Efficacy, Safety

Ping Wang, Yanqiu Wang, Hui Qiao, Jiao Gao, Kaili Zhang, Meishu Zhao. Effect of intrathoracic-intraperitoneal perfusion chemotherapy followed by high-frequency hyperthermia therapy in elderly patients with malignant pleural and peritoneal effusions[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2024, 11(02): 15-19.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2024.02.004

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2024/V11/I02/15

Figures/Tables 2

References 16

[1]	李金金，轩伟霞，张晓菊.恶性胸腔积液产生的机制研究进展[J].国际呼吸杂志，2018，38（10）：783-786.
[2]	Wang Y, Sun Y, Li X, et al. Progress in the treatment of malignant ascites[J]. Crit Rev Oncol Hematol, 2024, 194:104237.
[3]	王雪，吴明军，姚文静，等.复发性恶性胸腔积液的危险因素及治疗研究进展[J].临床肺科杂志，2023，28（6）：938-941.
[4]	贾闵羽，李庆霞，尹岳松.恶性胸腔积液引流和治疗的研究进展[J].癌症进展，2021，19（21）：2180-2181.
[5]	Lew M, Cantley R, Heider A, et al. Diagnosis and categorization of malignant effusions: A 6-year review from a single academic institution[J]. Diagn Cytopathol, 2021, 49(5):615-621.
[6]	李雯.持续热灌注腹腔化疗结合体外高频热疗治疗恶性腹腔积液的临床观察[J].中国医疗器械信息，2023，29（10）：51-53.
[7]	张海洋，宋展，钱国武.高频热疗、腹腔热灌注化疗联合静脉化疗对局部复发直肠癌的疗效分析[J].实用癌症杂志，2020，35（10）：1700-1702.
[8]	周际昌.实用肿瘤内科学[M].北京：人民卫生出版社，2010：29-30.
[9]	Ikegami T, Ishiki H, Kadono T, et al. Narrative review of malignant ascites: Epidemiology, pathophysiology, assessment, and treatment[J]. Ann Palliat Med, 2024, 13(4):842-857.
[10]	Bleicher J, Lambert LA. A palliative approach to management of peritoneal carcinomatosis and malignant ascites[J]. Surg Oncol Clin N Am, 2021, 30(3):475-490.
[11]	赵芳，姜国荣，王紫汀，等.深部热疗辅助常规治疗类炎性胸腔积液对患者肺通气功能和炎性反应水平的影响[J].中国医药导报，2020，17（13）：110-113.
[12]	蒋晓睿，王丽红，赖静.腹腔热灌注化疗序贯高频热疗治疗恶性腹腔积液的疗效观察[J].四川医学，2023，44（7）：689-692.
[13]	莫丽钦，丁玲玉，刘雅娟，等.高频深部热疗联合GP化疗方案治疗晚期卵巢癌合并腹腔积液的效果观察[J].全科医学临床与教育，2022，20（9）：783-787.
[14]	李燕明，王翠峰，任美英.联合检测肿瘤标志物对良恶性胸腔积液的诊断价值[J].包头医学院学报，2023，39（2）：36-40.
[15]	程晓云，肖敬，张淑平.高频热疗并顺铂腔内化疗治疗恶性胸腔积液疗效分析[J].现代肿瘤医学，2020，28（21）：3715-3718.
[16]	Yu T, Shu L, Chen Y, et al. Diagnosis of malignant versus tuberculous ascites using tumor markers and globulin ratios in serum and ascites: A Fisher discriminant model[J]. Arab J Gastroenterol, 2021, 22(2):93-98.

组别	例数	癌胚抗原（ng/mL）				糖类抗原125（U/mL）				糖类抗原199（U/mL）
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	100	115±30	33±6	26.803	<0.05	420±101	82±15	33.102	<0.05	287±82	46±9	29.215	<0.05
对照组	100	111±30	37±7	24.021	<0.05	407±110	99±17	26.671	<0.05	281±80	66±10	26.667	<0.05
t值		0.948	4.574			0.861	7.125			0.459	14.153
P值		>0.05	<0.01			>0.05	<0.01			>0.05	<0.01

组别	例数	癌胚抗原（ng/mL）				糖类抗原125（U/mL）				糖类抗原199（U/mL）
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
观察组	100	115±30	33±6	26.803	<0.05	420±101	82±15	33.102	<0.05	287±82	46±9	29.215	<0.05
对照组	100	111±30	37±7	24.021	<0.05	407±110	99±17	26.671	<0.05	281±80	66±10	26.667	<0.05
t值		0.948	4.574			0.861	7.125			0.459	14.153
P值		>0.05	<0.01			>0.05	<0.01			>0.05	<0.01

组别	例数	消化道症状	中性粒细胞减少	血小板减少	肝功能不全	肾功能不全
观察组	100	20（20.0）	14（14.0）	12（12.0）	8（8.0）	6（6.0）
对照组	100	18（18.0）	12（12.0）	11（11.0）	7（7.0）	5（5.0）
χ²值		0.130	0.177	0.411	0.072	0.096
P值		>0.05	>0.05	>0.05	>0.05	>0.05

组别	例数	消化道症状	中性粒细胞减少	血小板减少	肝功能不全	肾功能不全
观察组	100	20（20.0）	14（14.0）	12（12.0）	8（8.0）	6（6.0）
对照组	100	18（18.0）	12（12.0）	11（11.0）	7（7.0）	5（5.0）
χ²值		0.130	0.177	0.411	0.072	0.096
P值		>0.05	>0.05	>0.05	>0.05	>0.05

Please choose a citation manager

Content to export